Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $0.870
America/New_York / 31 des 1970 @ 19:00
RATING 2022-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/19 | 2/19 | 4/19 | 2/20 | 4/20 | 2/21 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | n/a | n/a | n/a |
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.227 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.227 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.713 - 1.027 ( +/- 18.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2005-04-18 | Orbimed Advisors Llc | Buy | 0 | Not reporting securities information. |
2004-06-30 | Stahl Pamela J | Buy | 17 500 | Stock Option (Right to Buy) |
2004-06-15 | Champsi Farah | Buy | 5 000 | Non-employee Director Stock Options (Right to Buy) |
2004-06-15 | Vida Julius A | Buy | 5 000 | Non-employee Director Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 3 transactions |
Buy: 27 500 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.870 (0.00% ) |
Volume | 0.941 mill |
Avg. Vol. | 1.379 mill |
% of Avg. Vol | 68.28 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.